The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
Synopsis
The global Glucagon Like Peptide-1 (GLP-1) Agonists market size was US$ 108120 million in 2024 and is forecast to a readjusted size of US$ 490060 million by 2031 with a CAGR of 24.5% during the forecast period 2025-2031.
Glucagon like peptide-1 (GLP-1) agonists is the agonists of the GLP-1 receptor. This class of drugs is used for the treatment of type 2 diabetes. One of their advantages is over older insulin secretagogues, such as sulfonylureas or meglitinides, and they have a lower risk of causing hypoglycemia.
The Glucagon-Like Peptide-1 (GLP-1) Agonists market, which focuses on drugs used for treating type 2 diabetes and obesity, is influenced by several important drivers and challenges:
Market Drivers:
Rising Prevalence of Diabetes and Obesity: The increasing global incidence of type 2 diabetes and obesity is driving demand for GLP-1 agonists, as they are effective in controlling blood sugar levels and aiding weight loss.
Shift Towards Injectable and Oral Therapies: Growing patient acceptance of injectable therapies (such as GLP-1 agonists) and the introduction of oral GLP-1 agonists (like semaglutide) are expanding the market.
Favorable Clinical Outcomes: GLP-1 agonists have shown promising results in managing glycemic control, cardiovascular risk reduction, and weight management, making them a preferred option among healthcare providers.
Increased Awareness and Screening: Governments and healthcare organizations are running campaigns to increase awareness about diabetes management, which is boosting demand for GLP-1 agonists.
Product Innovations: Continuous innovations and the development of longer-acting GLP-1 formulations with fewer side effects are improving patient compliance and market growth.
Market Challenges:
High Treatment Costs: GLP-1 agonists tend to be expensive, which can limit access, particularly in low-income or underdeveloped healthcare systems.
Side Effects and Contraindications: Some patients experience gastrointestinal side effects (like nausea and vomiting) with GLP-1 agonists, potentially limiting widespread use.
Competition from Other Diabetes Treatments: While GLP-1 agonists are effective, there is stiff competition from other diabetes drugs, including DPP-4 inhibitors, SGLT2 inhibitors, and insulin therapies.
Patient Adherence: Although the drug is effective, some patients may struggle with the required injections (for injectable GLP-1 agonists) or discontinuation due to side effects, leading to adherence challenges.
Regulatory and Reimbursement Barriers: The approval process for new GLP-1 agonist formulations, coupled with inconsistent reimbursement policies, can hinder the availability of these drugs in certain markets.
Novo Nordisk, AstraZeneca, Eli Lilly, GSK and Sanofi are the leader of the industry. Novo Nordisk is the top one of this industry. United States is the largest consumer of Glucagon like peptide-1 (GLP-1) agonists The second place is Europe.
The global Glucagon Like Peptide-1 (GLP-1) Agonists market is strategically segmented by company, region (country), by Type, and by Application. This report empowers stakeholders to capitalize on emerging opportunities, optimize product strategies, and outperform competitors through data-driven insights on sales, revenue, and forecasts across regions, by Type, and by Application for 2020-2031.
Market Segmentation
By Company:
Novo Nordisk
Eli Lilly
AstraZeneca
Sanofi
GSK
Hanson
Shanghai Benemae
By Type: (Dominant Segment vs High-Margin Innovation)
Dulaglutide
Exenatide
Liraglutide
Benaglutide
Other
By Application: (Core Demand Driver vs Emerging Opportunity)
Diabetes
Obesity
By Region
Macro-Regional Analysis: Market Size & Growth Forecasts
- North America
- Europe
- Asia-Pacific
- South America
- Middle East & Africa
Micro-Local Market Deep Dive: Strategic Insights
- Competitive Landscape: Player dominance vs. disruptors (e.g., Novo Nordisk in Europe)
- Emerging Product Trends: Dulaglutide adoption vs. Exenatide premiumization
- Demand-Side Dynamics: Diabetes growth in China vs. Obesity potential in North America
- Localized Consumer Needs: Regulatory hurdles in EU vs. price sensitivity in India
Focus Markets:
North America
Europe
China
Japan
Chapter Outline
Chapter 1: Report scope, executive summary, and market evolution scenarios (short/mid/long term).
Chapter 2: Quantitative analysis of Glucagon Like Peptide-1 (GLP-1) Agonists market size and growth potential at global, regional, and country levels.
Chapter 3: Competitive benchmarking of manufacturers (revenue, market share, M&A, R&D focus).
Chapter 4: Type-based segmentation analysis – Uncovering blue ocean markets (e.g., Exenatide in China).
Chapter 5: Application-based segmentation analysis – High-growth downstream opportunities (e.g., Obesity in India).
Chapter 6: Regional sales and revenue breakdown by company, type, application and customer.
Chapter 7: Key manufacturer profiles – Financials, product portfolios, and strategic developments.
Chapter 8: Market dynamics – Drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 9: Actionable conclusions and strategic recommendations.
Why This Report?
This is not just another market study. By fusing global trend analysis with hyper-local operational intelligence, we deliver:
- Risk-Controlled Market Entry: Navigate regulatory complexities in focus markets (e.g., China’s policies).
- Product Portfolio Optimization: Align offerings with regional preferences (e.g., Dulaglutide dominance in Europe vs. Exenatide demand in MEA).
- Competitor Counterstrategies: Decode player tactics in fragmented vs. consolidated markets.
The global Glucagon Like Peptide-1 (GLP-1) Agonists market size was US$ 108120 million in 2024 and is forecast to a readjusted size of US$ 490060 million by 2031 with a CAGR of 24.5% during the forecast period 2025-2031.
Glucagon like peptide-1 (GLP-1) agonists is the agonists of the GLP-1 receptor. This class of drugs is used for the treatment of type 2 diabetes. One of their advantages is over older insulin secretagogues, such as sulfonylureas or meglitinides, and they have a lower risk of causing hypoglycemia.
The Glucagon-Like Peptide-1 (GLP-1) Agonists market, which focuses on drugs used for treating type 2 diabetes and obesity, is influenced by several important drivers and challenges:
Market Drivers:
Rising Prevalence of Diabetes and Obesity: The increasing global incidence of type 2 diabetes and obesity is driving demand for GLP-1 agonists, as they are effective in controlling blood sugar levels and aiding weight loss.
Shift Towards Injectable and Oral Therapies: Growing patient acceptance of injectable therapies (such as GLP-1 agonists) and the introduction of oral GLP-1 agonists (like semaglutide) are expanding the market.
Favorable Clinical Outcomes: GLP-1 agonists have shown promising results in managing glycemic control, cardiovascular risk reduction, and weight management, making them a preferred option among healthcare providers.
Increased Awareness and Screening: Governments and healthcare organizations are running campaigns to increase awareness about diabetes management, which is boosting demand for GLP-1 agonists.
Product Innovations: Continuous innovations and the development of longer-acting GLP-1 formulations with fewer side effects are improving patient compliance and market growth.
Market Challenges:
High Treatment Costs: GLP-1 agonists tend to be expensive, which can limit access, particularly in low-income or underdeveloped healthcare systems.
Side Effects and Contraindications: Some patients experience gastrointestinal side effects (like nausea and vomiting) with GLP-1 agonists, potentially limiting widespread use.
Competition from Other Diabetes Treatments: While GLP-1 agonists are effective, there is stiff competition from other diabetes drugs, including DPP-4 inhibitors, SGLT2 inhibitors, and insulin therapies.
Patient Adherence: Although the drug is effective, some patients may struggle with the required injections (for injectable GLP-1 agonists) or discontinuation due to side effects, leading to adherence challenges.
Regulatory and Reimbursement Barriers: The approval process for new GLP-1 agonist formulations, coupled with inconsistent reimbursement policies, can hinder the availability of these drugs in certain markets.
Novo Nordisk, AstraZeneca, Eli Lilly, GSK and Sanofi are the leader of the industry. Novo Nordisk is the top one of this industry. United States is the largest consumer of Glucagon like peptide-1 (GLP-1) agonists The second place is Europe.
The global Glucagon Like Peptide-1 (GLP-1) Agonists market is strategically segmented by company, region (country), by Type, and by Application. This report empowers stakeholders to capitalize on emerging opportunities, optimize product strategies, and outperform competitors through data-driven insights on sales, revenue, and forecasts across regions, by Type, and by Application for 2020-2031.
Market Segmentation
By Company:
Novo Nordisk
Eli Lilly
AstraZeneca
Sanofi
GSK
Hanson
Shanghai Benemae
By Type: (Dominant Segment vs High-Margin Innovation)
Dulaglutide
Exenatide
Liraglutide
Benaglutide
Other
By Application: (Core Demand Driver vs Emerging Opportunity)
Diabetes
Obesity
By Region
Macro-Regional Analysis: Market Size & Growth Forecasts
- North America
- Europe
- Asia-Pacific
- South America
- Middle East & Africa
Micro-Local Market Deep Dive: Strategic Insights
- Competitive Landscape: Player dominance vs. disruptors (e.g., Novo Nordisk in Europe)
- Emerging Product Trends: Dulaglutide adoption vs. Exenatide premiumization
- Demand-Side Dynamics: Diabetes growth in China vs. Obesity potential in North America
- Localized Consumer Needs: Regulatory hurdles in EU vs. price sensitivity in India
Focus Markets:
North America
Europe
China
Japan
Chapter Outline
Chapter 1: Report scope, executive summary, and market evolution scenarios (short/mid/long term).
Chapter 2: Quantitative analysis of Glucagon Like Peptide-1 (GLP-1) Agonists market size and growth potential at global, regional, and country levels.
Chapter 3: Competitive benchmarking of manufacturers (revenue, market share, M&A, R&D focus).
Chapter 4: Type-based segmentation analysis – Uncovering blue ocean markets (e.g., Exenatide in China).
Chapter 5: Application-based segmentation analysis – High-growth downstream opportunities (e.g., Obesity in India).
Chapter 6: Regional sales and revenue breakdown by company, type, application and customer.
Chapter 7: Key manufacturer profiles – Financials, product portfolios, and strategic developments.
Chapter 8: Market dynamics – Drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 9: Actionable conclusions and strategic recommendations.
Why This Report?
This is not just another market study. By fusing global trend analysis with hyper-local operational intelligence, we deliver:
- Risk-Controlled Market Entry: Navigate regulatory complexities in focus markets (e.g., China’s policies).
- Product Portfolio Optimization: Align offerings with regional preferences (e.g., Dulaglutide dominance in Europe vs. Exenatide demand in MEA).
- Competitor Counterstrategies: Decode player tactics in fragmented vs. consolidated markets.
Index1 Market Overview
1.1 Glucagon Like Peptide-1 (GLP-1) Agonists Product Scope
1.2 Glucagon Like Peptide-1 (GLP-1) Agonists by Type
1.2.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Type (2020 & 2024 & 2031)
1.2.2 Dulaglutide
1.2.3 Exenatide
1.2.4 Liraglutide
1.2.5 Benaglutide
1.2.6 Other
1.3 Glucagon Like Peptide-1 (GLP-1) Agonists by Application
1.3.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Comparison by Application (2020 & 2024 & 2031)
1.3.2 Diabetes
1.3.3 Obesity
1.4 Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Estimates and Forecasts (2020-2031)
1.4.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Size in Value Growth Rate (2020-2031)
1.4.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Size in Volume Growth Rate (2020-2031)
1.4.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Price Trends (2020-2031)
1.5 Assumptions and Limitations
2 Market Size and Prospective by Region
2.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Size by Region: 2020 VS 2024 VS 2031
2.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Retrospective Market Scenario by Region (2020-2025)
2.2.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Region (2020-2025)
2.2.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Region (2020-2025)
2.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Estimates and Forecasts by Region (2026-2031)
2.3.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Estimates and Forecasts by Region (2026-2031)
2.3.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Forecast by Region (2026-2031)
2.4 Major Region and Emerging Market Analysis
2.4.1 North America Glucagon Like Peptide-1 (GLP-1) Agonists Market Size and Prospective (2020-2031)
2.4.2 Europe Glucagon Like Peptide-1 (GLP-1) Agonists Market Size and Prospective (2020-2031)
2.4.3 China Glucagon Like Peptide-1 (GLP-1) Agonists Market Size and Prospective (2020-2031)
2.4.4 Japan Glucagon Like Peptide-1 (GLP-1) Agonists Market Size and Prospective (2020-2031)
3 Global Market Size by Type
3.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Historic Market Review by Type (2020-2025)
3.1.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Type (2020-2025)
3.1.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Type (2020-2025)
3.1.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Price by Type (2020-2025)
3.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Estimates and Forecasts by Type (2026-2031)
3.2.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Forecast by Type (2026-2031)
3.2.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Forecast by Type (2026-2031)
3.2.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Price Forecast by Type (2026-2031)
3.3 Different Types Glucagon Like Peptide-1 (GLP-1) Agonists Representative Players
4 Global Market Size by Application
4.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Historic Market Review by Application (2020-2025)
4.1.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Application (2020-2025)
4.1.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Application (2020-2025)
4.1.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Price by Application (2020-2025)
4.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Estimates and Forecasts by Application (2026-2031)
4.2.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Forecast by Application (2026-2031)
4.2.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Forecast by Application (2026-2031)
4.2.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Price Forecast by Application (2026-2031)
4.3 New Sources of Growth in Glucagon Like Peptide-1 (GLP-1) Agonists Application
5 Competition Landscape by Players
5.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Players (2020-2025)
5.2 Global Top Glucagon Like Peptide-1 (GLP-1) Agonists Players by Revenue (2020-2025)
5.3 Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Glucagon Like Peptide-1 (GLP-1) Agonists as of 2024)
5.4 Global Glucagon Like Peptide-1 (GLP-1) Agonists Average Price by Company (2020-2025)
5.5 Global Key Manufacturers of Glucagon Like Peptide-1 (GLP-1) Agonists, Manufacturing Sites & Headquarters
5.6 Global Key Manufacturers of Glucagon Like Peptide-1 (GLP-1) Agonists, Product Type & Application
5.7 Global Key Manufacturers of Glucagon Like Peptide-1 (GLP-1) Agonists, Date of Enter into This Industry
5.8 Manufacturers Mergers & Acquisitions, Expansion Plans
6 Region Analysis
6.1 North America Market: Players, Segments, Downstream and Major Customers
6.1.1 North America Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Company
6.1.1.1 North America Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Company (2020-2025)
6.1.1.2 North America Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Company (2020-2025)
6.1.2 North America Glucagon Like Peptide-1 (GLP-1) Agonists Sales Breakdown by Type (2020-2025)
6.1.3 North America Glucagon Like Peptide-1 (GLP-1) Agonists Sales Breakdown by Application (2020-2025)
6.1.4 North America Glucagon Like Peptide-1 (GLP-1) Agonists Major Customer
6.1.5 North America Market Trend and Opportunities
6.2 Europe Market: Players, Segments, Downstream and Major Customers
6.2.1 Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Company
6.2.1.1 Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Company (2020-2025)
6.2.1.2 Europe Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Company (2020-2025)
6.2.2 Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales Breakdown by Type (2020-2025)
6.2.3 Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales Breakdown by Application (2020-2025)
6.2.4 Europe Glucagon Like Peptide-1 (GLP-1) Agonists Major Customer
6.2.5 Europe Market Trend and Opportunities
6.3 China Market: Players, Segments, Downstream and Major Customers
6.3.1 China Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Company
6.3.1.1 China Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Company (2020-2025)
6.3.1.2 China Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Company (2020-2025)
6.3.2 China Glucagon Like Peptide-1 (GLP-1) Agonists Sales Breakdown by Type (2020-2025)
6.3.3 China Glucagon Like Peptide-1 (GLP-1) Agonists Sales Breakdown by Application (2020-2025)
6.3.4 China Glucagon Like Peptide-1 (GLP-1) Agonists Major Customer
6.3.5 China Market Trend and Opportunities
6.4 Japan Market: Players, Segments, Downstream and Major Customers
6.4.1 Japan Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Company
6.4.1.1 Japan Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Company (2020-2025)
6.4.1.2 Japan Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Company (2020-2025)
6.4.2 Japan Glucagon Like Peptide-1 (GLP-1) Agonists Sales Breakdown by Type (2020-2025)
6.4.3 Japan Glucagon Like Peptide-1 (GLP-1) Agonists Sales Breakdown by Application (2020-2025)
6.4.4 Japan Glucagon Like Peptide-1 (GLP-1) Agonists Major Customer
6.4.5 Japan Market Trend and Opportunities
7 Company Profiles and Key Figures
7.1 Novo Nordisk
7.1.1 Novo Nordisk Company Information
7.1.2 Novo Nordisk Business Overview
7.1.3 Novo Nordisk Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Revenue and Gross Margin (2020-2025)
7.1.4 Novo Nordisk Glucagon Like Peptide-1 (GLP-1) Agonists Products Offered
7.1.5 Novo Nordisk Recent Development
7.2 Eli Lilly
7.2.1 Eli Lilly Company Information
7.2.2 Eli Lilly Business Overview
7.2.3 Eli Lilly Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Revenue and Gross Margin (2020-2025)
7.2.4 Eli Lilly Glucagon Like Peptide-1 (GLP-1) Agonists Products Offered
7.2.5 Eli Lilly Recent Development
7.3 AstraZeneca
7.3.1 AstraZeneca Company Information
7.3.2 AstraZeneca Business Overview
7.3.3 AstraZeneca Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Revenue and Gross Margin (2020-2025)
7.3.4 AstraZeneca Glucagon Like Peptide-1 (GLP-1) Agonists Products Offered
7.3.5 AstraZeneca Recent Development
7.4 Sanofi
7.4.1 Sanofi Company Information
7.4.2 Sanofi Business Overview
7.4.3 Sanofi Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Revenue and Gross Margin (2020-2025)
7.4.4 Sanofi Glucagon Like Peptide-1 (GLP-1) Agonists Products Offered
7.4.5 Sanofi Recent Development
7.5 GSK
7.5.1 GSK Company Information
7.5.2 GSK Business Overview
7.5.3 GSK Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Revenue and Gross Margin (2020-2025)
7.5.4 GSK Glucagon Like Peptide-1 (GLP-1) Agonists Products Offered
7.5.5 GSK Recent Development
7.6 Hanson
7.6.1 Hanson Company Information
7.6.2 Hanson Business Overview
7.6.3 Hanson Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Revenue and Gross Margin (2020-2025)
7.6.4 Hanson Glucagon Like Peptide-1 (GLP-1) Agonists Products Offered
7.6.5 Hanson Recent Development
7.7 Shanghai Benemae
7.7.1 Shanghai Benemae Company Information
7.7.2 Shanghai Benemae Business Overview
7.7.3 Shanghai Benemae Glucagon Like Peptide-1 (GLP-1) Agonists Sales, Revenue and Gross Margin (2020-2025)
7.7.4 Shanghai Benemae Glucagon Like Peptide-1 (GLP-1) Agonists Products Offered
7.7.5 Shanghai Benemae Recent Development
8 Glucagon Like Peptide-1 (GLP-1) Agonists Manufacturing Cost Analysis
8.1 Glucagon Like Peptide-1 (GLP-1) Agonists Key Raw Materials Analysis
8.1.1 Key Raw Materials
8.1.2 Key Suppliers of Raw Materials
8.2 Proportion of Manufacturing Cost Structure
8.3 Manufacturing Process Analysis of Glucagon Like Peptide-1 (GLP-1) Agonists
8.4 Glucagon Like Peptide-1 (GLP-1) Agonists Industrial Chain Analysis
9 Marketing Channel, Distributors and Customers
9.1 Marketing Channel
9.2 Glucagon Like Peptide-1 (GLP-1) Agonists Distributors List
9.3 Glucagon Like Peptide-1 (GLP-1) Agonists Customers
10 Glucagon Like Peptide-1 (GLP-1) Agonists Market Dynamics
10.1 Glucagon Like Peptide-1 (GLP-1) Agonists Industry Trends
10.2 Glucagon Like Peptide-1 (GLP-1) Agonists Market Drivers
10.3 Glucagon Like Peptide-1 (GLP-1) Agonists Market Challenges
10.4 Glucagon Like Peptide-1 (GLP-1) Agonists Market Restraints
11 Research Findings and Conclusion
12 Appendix
12.1 Research Methodology
12.1.1 Methodology/Research Approach
12.1.1.1 Research Programs/Design
12.1.1.2 Market Size Estimation
12.1.1.3 Market Breakdown and Data Triangulation
12.1.2 Data Source
12.1.2.1 Secondary Sources
12.1.2.2 Primary Sources
12.2 Author Details
12.3 Disclaimer
List of TablesList of Tables
Table 1. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales (US$ Million) Growth Rate by Type (2020 & 2024 & 2031)
Table 2. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales (US$ Million) Comparison by Application (2020 & 2024 & 2031)
Table 3. Global Market Glucagon Like Peptide-1 (GLP-1) Agonists Market Size (US$ Million) by Region:2020 VS 2024 VS 2031
Table 4. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units) by Region (2020-2025)
Table 5. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Region (2020-2025)
Table 6. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue (US$ Million) Market Share by Region (2020-2025)
Table 7. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Share by Region (2020-2025)
Table 8. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units) Forecast by Region (2026-2031)
Table 9. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share Forecast by Region (2026-2031)
Table 10. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue (US$ Million) Forecast by Region (2026-2031)
Table 11. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Share Forecast by Region (2026-2031)
Table 12. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Type (K Units) & (2020-2025)
Table 13. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Share by Type (2020-2025)
Table 14. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Type (US$ Million) & (2020-2025)
Table 15. Global Glucagon Like Peptide-1 (GLP-1) Agonists Price by Type (USD/Unit) & (2020-2025)
Table 16. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Type (K Units) & (2026-2031)
Table 17. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Type (US$ Million) & (2026-2031)
Table 18. Global Glucagon Like Peptide-1 (GLP-1) Agonists Price by Type (USD/Unit) & (2026-2031)
Table 19. Representative Players of Each Type
Table 20. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Application (K Units) & (2020-2025)
Table 21. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Share by Application (2020-2025)
Table 22. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Application (US$ Million) & (2020-2025)
Table 23. Global Glucagon Like Peptide-1 (GLP-1) Agonists Price by Application (USD/Unit) & (2020-2025)
Table 24. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Application (K Units) & (2026-2031)
Table 25. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Application (US$ Million) & (2026-2031)
Table 26. Global Glucagon Like Peptide-1 (GLP-1) Agonists Price by Application (USD/Unit) & (2026-2031)
Table 27. New Sources of Growth in Glucagon Like Peptide-1 (GLP-1) Agonists Application
Table 28. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Company (K Units) & (2020-2025)
Table 29. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Share by Company (2020-2025)
Table 30. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Company (US$ Million) & (2020-2025)
Table 31. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Share by Company (2020-2025)
Table 32. Global Glucagon Like Peptide-1 (GLP-1) Agonists by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Glucagon Like Peptide-1 (GLP-1) Agonists as of 2024)
Table 33. Global Market Glucagon Like Peptide-1 (GLP-1) Agonists Average Price by Company (USD/Unit) & (2020-2025)
Table 34. Global Key Manufacturers of Glucagon Like Peptide-1 (GLP-1) Agonists, Manufacturing Sites & Headquarters
Table 35. Global Key Manufacturers of Glucagon Like Peptide-1 (GLP-1) Agonists, Product Type & Application
Table 36. Global Key Manufacturers of Glucagon Like Peptide-1 (GLP-1) Agonists, Date of Enter into This Industry
Table 37. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 38. North America Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Company (2020-2025) & (K Units)
Table 39. North America Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Company (2020-2025)
Table 40. North America Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Company (2020-2025) & (US$ Million)
Table 41. North America Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Company (2020-2025)
Table 42. North America Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Type (2020-2025) & (K Units)
Table 43. North America Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Type (2020-2025)
Table 44. North America Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Application (2020-2025) & (K Units)
Table 45. North America Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Application (2020-2025)
Table 46. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Company (2020-2025) & (K Units)
Table 47. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Company (2020-2025)
Table 48. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Company (2020-2025) & (US$ Million)
Table 49. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Company (2020-2025)
Table 50. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Type (2020-2025) & (K Units)
Table 51. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Type (2020-2025)
Table 52. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Application (2020-2025) & (K Units)
Table 53. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Application (2020-2025)
Table 54. China Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Company (2020-2025) & (K Units)
Table 55. China Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Company (2020-2025)
Table 56. China Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Company (2020-2025) & (US$ Million)
Table 57. China Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Company (2020-2025)
Table 58. China Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Type (2020-2025) & (K Units)
Table 59. China Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Type (2020-2025)
Table 60. China Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Application (2020-2025) & (K Units)
Table 61. China Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Application (2020-2025)
Table 62. Japan Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Company (2020-2025) & (K Units)
Table 63. Japan Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Company (2020-2025)
Table 64. Japan Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Company (2020-2025) & (US$ Million)
Table 65. Japan Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Company (2020-2025)
Table 66. Japan Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Type (2020-2025) & (K Units)
Table 67. Japan Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Type (2020-2025)
Table 68. Japan Glucagon Like Peptide-1 (GLP-1) Agonists Sales by Application (2020-2025) & (K Units)
Table 69. Japan Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Application (2020-2025)
Table 70. Novo Nordisk Company Information
Table 71. Novo Nordisk Description and Business Overview
Table 72. Novo Nordisk Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 73. Novo Nordisk Glucagon Like Peptide-1 (GLP-1) Agonists Product
Table 74. Novo Nordisk Recent Development
Table 75. Eli Lilly Company Information
Table 76. Eli Lilly Description and Business Overview
Table 77. Eli Lilly Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 78. Eli Lilly Glucagon Like Peptide-1 (GLP-1) Agonists Product
Table 79. Eli Lilly Recent Development
Table 80. AstraZeneca Company Information
Table 81. AstraZeneca Description and Business Overview
Table 82. AstraZeneca Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 83. AstraZeneca Glucagon Like Peptide-1 (GLP-1) Agonists Product
Table 84. AstraZeneca Recent Development
Table 85. Sanofi Company Information
Table 86. Sanofi Description and Business Overview
Table 87. Sanofi Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 88. Sanofi Glucagon Like Peptide-1 (GLP-1) Agonists Product
Table 89. Sanofi Recent Development
Table 90. GSK Company Information
Table 91. GSK Description and Business Overview
Table 92. GSK Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 93. GSK Glucagon Like Peptide-1 (GLP-1) Agonists Product
Table 94. GSK Recent Development
Table 95. Hanson Company Information
Table 96. Hanson Description and Business Overview
Table 97. Hanson Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 98. Hanson Glucagon Like Peptide-1 (GLP-1) Agonists Product
Table 99. Hanson Recent Development
Table 100. Shanghai Benemae Company Information
Table 101. Shanghai Benemae Description and Business Overview
Table 102. Shanghai Benemae Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 103. Shanghai Benemae Glucagon Like Peptide-1 (GLP-1) Agonists Product
Table 104. Shanghai Benemae Recent Development
Table 105. Production Base and Market Concentration Rate of Raw Material
Table 106. Key Suppliers of Raw Materials
Table 107. Glucagon Like Peptide-1 (GLP-1) Agonists Distributors List
Table 108. Glucagon Like Peptide-1 (GLP-1) Agonists Customers List
Table 109. Glucagon Like Peptide-1 (GLP-1) Agonists Market Trends
Table 110. Glucagon Like Peptide-1 (GLP-1) Agonists Market Drivers
Table 111. Glucagon Like Peptide-1 (GLP-1) Agonists Market Challenges
Table 112. Glucagon Like Peptide-1 (GLP-1) Agonists Market Restraints
Table 113. Research Programs/Design for This Report
Table 114. Key Data Information from Secondary Sources
Table 115. Key Data Information from Primary Sources
List of Figures
Figure 1. Glucagon Like Peptide-1 (GLP-1) Agonists Product Picture
Figure 2. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales (US$ Million) by Type (2020 & 2024 & 2031)
Figure 3. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Type in 2024 & 2031
Figure 4. Dulaglutide Product Picture
Figure 5. Exenatide Product Picture
Figure 6. Liraglutide Product Picture
Figure 7. Benaglutide Product Picture
Figure 8. Other Product Picture
Figure 9. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales (US$ Million) by Application (2020 & 2024 & 2031)
Figure 10. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Share by Application in 2024 & 2031
Figure 11. Diabetes Examples
Figure 12. Obesity Examples
Figure 13. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales, (US$ Million), 2020 VS 2024 VS 2031
Figure 14. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Growth Rate (2020-2031) & (US$ Million)
Figure 15. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units) Growth Rate (2020-2031)
Figure 16. Global Glucagon Like Peptide-1 (GLP-1) Agonists Price Trends Growth Rate (2020-2031) & (USD/Unit)
Figure 17. Glucagon Like Peptide-1 (GLP-1) Agonists Report Years Considered
Figure 18. Global Market Glucagon Like Peptide-1 (GLP-1) Agonists Market Size (US$ Million) by Region:2020 VS 2024 VS 2031
Figure 19. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Market Share by Region: 2020 VS 2024
Figure 20. North America Glucagon Like Peptide-1 (GLP-1) Agonists Revenue (US$ Million) Growth Rate (2020-2031)
Figure 21. North America Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units) Growth Rate (2020-2031)
Figure 22. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Revenue (US$ Million) Growth Rate (2020-2031)
Figure 23. Europe Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units) Growth Rate (2020-2031)
Figure 24. China Glucagon Like Peptide-1 (GLP-1) Agonists Revenue (US$ Million) Growth Rate (2020-2031)
Figure 25. China Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units) Growth Rate (2020-2031)
Figure 26. Japan Glucagon Like Peptide-1 (GLP-1) Agonists Revenue (US$ Million) Growth Rate (2020-2031)
Figure 27. Japan Glucagon Like Peptide-1 (GLP-1) Agonists Sales (K Units) Growth Rate (2020-2031)
Figure 28. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Share by Type (2020-2025)
Figure 29. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Share by Type (2026-2031)
Figure 30. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Share by Type (2026-2031)
Figure 31. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Share by Application (2020-2025)
Figure 32. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Growth Rate by Application in 2020 & 2024
Figure 33. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Share by Application (2026-2031)
Figure 34. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Share by Application (2026-2031)
Figure 35. Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Share by Company (2024)
Figure 36. Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Share by Company (2024)
Figure 37. Global 5 Largest Glucagon Like Peptide-1 (GLP-1) Agonists Players Market Share by Revenue in Glucagon Like Peptide-1 (GLP-1) Agonists: 2020 & 2024
Figure 38. Glucagon Like Peptide-1 (GLP-1) Agonists Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
Figure 39. Manufacturing Cost Structure of Glucagon Like Peptide-1 (GLP-1) Agonists
Figure 40. Manufacturing Process Analysis of Glucagon Like Peptide-1 (GLP-1) Agonists
Figure 41. Glucagon Like Peptide-1 (GLP-1) Agonists Industrial Chain
Figure 42. Channels of Distribution (Direct Vs Distribution)
Figure 43. Distributors Profiles
Figure 44. Bottom-up and Top-down Approaches for This Report
Figure 45. Data Triangulation
Figure 46. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
